Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia

What is it about?

Most treatment guidelines recommend to avoid antipsychotic polypharmacy due to safety issues but this is not based on any evidence. We studied the risk of severe physical morbidity in a nationwide cohort of patients with schizophrenia, and observed that these patients had about 20% higher risk of severe cardiovascular outcome leading to hospitalization during high-dose antipsychotic monotherapy than during time periods being treated with corresponding high-dose antipsychotic combination therapy, suggesting better safety for antipsychotic polypharmacy.

Featured Image